June 2024: Seattle Children's Hospital will initiate the inaugural clinical trial in the United States this summer to evaluate the efficacy of an autologous CAR T-cell treatment against a prevalent ki...
What is the Richter transformation? Richter transformation is an infrequent but not rare occurrence when an aggressive B-cell lymphoma develops in people with chronic lymphocytic leukemia or small ly...
Pancreatic cancer Pancreatic cancer, also referred to as the "king of cancers," is a highly deadly malignant tumor, with a survival rate of fewer than 10% over a 5-year period. As a result of inadequ...
OriCAR-017 for RRMM A top biopharmaceutical company in the clinical stage, Oricell Therapeutics, shared the long-term follow-up results of OriCAR-017, a Phase I study that looked at how well GPRC5D-t...
Results of SATRi-cel therapy CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) has released the latest findings from the investigator-initiated trial CT041-CG4006 (NCT03874897) of satricabt...
NK Cell therapy vs CAR T-Cell therapy The FDA's approval of the first CAR T cell therapy in 2017 was widely celebrated as a significant advancement in cancer treatment. The method enabled a focused a...
What is systemic lupus erythematosus? Systemic lupus erythematosus (SLE) is defined by an abnormal immune response, resulting in a highly varied clinical presentation that can potentially impact many...
SHANGHAI, China, April 30, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and sol...
The future of CAR T-cell therapy: an analysis of its rapid growth and expansion. Within the realm of contemporary medicine, CAR T-cell therapy emerges as an innovative and groundbreaking intervention...
Introduction In the domain of oncology, immunotherapy has emerged as a pioneering methodology, harnessing the body's immune system to combat malignant tumors. There are many immunotherapeutic approac...